AMSTERDAM, Dec 22 (Reuters) - Dutch biotechnology firm Crucell (CRCL.AS: Quote, Profile, Research) (CRXL.O: Quote, Profile, Research) announced three licensing agreements on Thursday for its PER.C6 gene technology, which uses human cells as a platform to produce vaccines and other drugs.
